Literature DB >> 1701012

Non-A, non-B hepatitis specific antibodies directed at host-derived epitope: implication for an autoimmune process.

S Mishiro1, Y Hoshi, K Takeda, A Yoshikawa, T Gotanda, K Takahashi, Y Akahane, H Yoshizawa, H Okamoto, F Tsuda.   

Abstract

A cDNA clone (GOR47-1) bearing an epitope with an aminoacid sequence GRRGQKAKSNPNRPL (GOR epitope) was isolated from the plasma of a laboratory chimpanzee infected with human non-A, non-B hepatitis (NANBH) agent. The epitope was not encoded by reported sequences of hepatitis C virus (HCV) but instead was coded for by a host cellular sequence. An enzyme-linked immunosorbent assay (ELISA) was developed for antibodies to the GOR epitope (anti-GOR). A patient with acute NANBH produced both IgM and IgG classes of anti-GOR in the acute phase of the illness, with concentrations of IgG class anti-GOR rising when anti-HCV became detectable. Anti-GOR was detected in serum from 59 (81%) of 73 patients with chronic NANBH, 40 (65%) of 62 with NANB liver cirrhosis, and 25 (63%) of 40 NANB patients with primary hepatocellular carcinoma, but in only less than 10% of patients with chronic liver diseases due to hepatitis B virus, alcohol, or an autoimmune disorder, and in only 2% of voluntary blood donors. Circulating HCV-RNA was detected by polymerase chain reaction (PCR) in most patients seropositive for anti-GOR but negative for anti-HCV. Detection of anti-GOR would therefore help in the diagnosis of NANBH and in reducing the occurrence of post-transfusion hepatitis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1701012     DOI: 10.1016/0140-6736(90)93101-t

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  24 in total

1.  Antibodies against hepatitis C virus in mixed cryoglobulinemia patients.

Authors:  C Ferri; F Greco; G Longombardo; P Palla; A Moretti; E Marzo; P V Fosella; G Pasero; S Bombardieri
Journal:  Infection       Date:  1991 Nov-Dec       Impact factor: 3.553

2.  The GOR gene product cannot cross-react with hepatitis C virus in humans.

Authors:  R Koike; T Iizuka; T Watanabe; N Miyasaka
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

3.  Effect of alpha-interferon on hepatitis C virus chronic infection in mixed cryoglobulinemia patients.

Authors:  C Ferri; A L Zignego; G Longombardo; M Monti; L La Civita; F Lombardini; F Greco; A Mazzoni; G Pasero; P Gentilini
Journal:  Infection       Date:  1993 Mar-Apr       Impact factor: 3.553

4.  Hepatitis C virus infection can mimic type 1 (antinuclear antibody positive) autoimmune chronic active hepatitis.

Authors:  J M Pawlotsky; L Deforges; S Bretagne; C André; J M Métreau; V Thiers; E S Zafrani; M Goossens; J Duval; J P Mavier
Journal:  Gut       Date:  1993       Impact factor: 23.059

Review 5.  Viral markers in the treatment of hepatitis B and C.

Authors:  H Schmilovitz-Weiss; M Levy; N Thompson; G Dusheiko
Journal:  Gut       Date:  1993       Impact factor: 23.059

6.  Clinical course of acute hepatitis C and changes in HCV markers.

Authors:  K Hino; S Sainokami; K Shimoda; H Niwa; S Iino
Journal:  Dig Dis Sci       Date:  1994-01       Impact factor: 3.199

7.  Hepatitis C virus detection is facilitated by the combined use of c100 protein and GOR epitope.

Authors:  J Hayashi; K Nakashima; M Hirata; A Noguchi; K Akazawa; Y Maeda; S Kashiwagi
Journal:  Gastroenterol Jpn       Date:  1992-10

8.  Overlap and discrepancy between tests for anti-C100, anti-GOR and anti-CP9 in patients with chronic liver disease and inhabitants in Saga, Japan.

Authors:  Y Setoguchi; K Yamamoto; I Ozaki; I Wada; T Hara; N Fujio; T Mizuta; T Sakai; F Nagumo; J Tadano
Journal:  Gastroenterol Jpn       Date:  1992-08

9.  Immune response to GOR, a marker for non-A, non-B hepatitis and its correlation with hepatitis C virus infection.

Authors:  S U Mehta; S Mishiro; K Sekiguchi; T Leung; G J Dawson; L M Pendy; D A Peterson; S G Devare
Journal:  J Clin Immunol       Date:  1992-05       Impact factor: 8.317

10.  Non-muscle myosin as target antigen for human autoantibodies in patients with hepatitis C virus-associated chronic liver diseases.

Authors:  C A von Mühlen; E K Chan; C L Peebles; H Imai; K Kiyosawa; E M Tan
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.